Doxy-PEP: Who, When, and How?

Doxy-PEP: Who, When, and How?


Annie F. Luetkemeyer, MD
University of California San Francisco


Connie L. Celum, MD, MPH
University of Washington

September 26, 2023

12:30 PM - 1:45 PM PT


Assessment of Needs

Given the increasing burden of gonorrhea, chlamydia, and syphilis infections in the US, effective tools are needed to fight against bacterial sexually transmitted infections (STIs). Doxycycline postexposure prophylaxis (doxy-PEP) is a sexual-health strategy that shows considerable promise in this endeavor. Drug formulations and recommendations for use continue to evolve, particularly for patients with HIV. Presented by Annie Luetkemeyer, MD, and moderated by Connie Celum, MD, this webinar reviews the current recommendations by the Centers for Disease Control and Prevention (CDC) for the use of doxy-PEP. Topics will include the criteria to determine appropriate candidates for doxy-PEP therapy, strategies for effective doxy-PEP administration, and questions that remain to be answered in future studies on doxy-PEP in patients with HIV.

Learning Objectives

 On completion of this activity, learners will be able to: 

  • Implement current CDC guidelines to determine which patients with HIV would benefit from doxy-PEP
  • Understand how and when to utilize doxy-PEP to reduce the incidence of sexually transmitted infections
  • Evaluate the ongoing unanswered questions regarding doxy-PEP use in patients with HIV


Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, September 26, 2023, 1:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.


Dr Luetkemeyer reported grants/grants pending to their institution from Gilead Sciences, Inc, and GlaxoSmithKline; consulting or advisor fees from Vir Biotechnology; non-cash provision of medicines, equipment, or administrative support to their institution from Mayne Pharma, Hologic, and Cepheid. (Updated July 26, 2023)


Dr Celum reported consulting or advising fees from Gilead Sciences, Inc. and Merck & Co, Inc; and expert testimony for Gilead Sciences, Inc. (Updated June 30, 2023)

COW Board

The financial relationships of the COW Board can be found here: 

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-22-536-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Janssen Therapeutics
Theratechnologies Inc.


Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.